CHEK1 and Miyoshi myopathy: RAS is the most commonly mutated gene in MM [4], and simultaneous inhibition of Checkpoint Kinase 1 (CHEK1) and MK2 MAPK Activated Protein Kinase 2 (MK2) has synergistic effects in suppressing KRAS-mutant cancer [15].